全球细胞治疗市场 – 行业趋势及 2030 年预测

细胞治疗市场分析和规模

细胞疗法的发生率可能因多种因素而异，包括细胞疗法的可用性和批准状态、所治疗的具体适应症或疾病以及特定地区的医疗保健基础设施和资源。细胞疗法是一个快速发展的领域，随着越来越多的疗法获得监管部门的批准并投入商业使用，细胞疗法治疗的发生率预计会增加。然而，值得注意的是，与更成熟的治疗方式相比，细胞疗法的发生率可能仍然相对较低，因为细胞疗法通常很复杂、个性化，并且可能仍处于采用的早期阶段。

Data Bridge Market Research 分析，2022 年全球细胞治疗市场规模为 148.92 亿美元，预计到 2030 年将达到 606.9642 亿美元，预计在 2023 年至 2030 年的预测期内复合年增长率为 19.2%。由于对用于治疗慢性疾病的更好的细胞和组织治疗方法的需求不断增长，“细胞永生化技术”在全球细胞治疗市场的技术领域占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 整理的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。

细胞治疗市场范围和细分

Market Definition

Cell therapy is a technology that relies on replacing diseased or dysfunctional cells with healthy functioning ones. Cells mainly used for such advanced therapies are stem cells, owing to their ability to differentiate into specific cells required for repairing damaged or defective tissues or cells.

Cell therapy finds its application in development of regenerative medicines, which is a multidisciplinary area aimed at maintenance, improvement, or restoration of cell, tissue, or organ function using methods mainly related to cell therapy.

Global Cell Therapy Market Dynamics

Drivers

• The Rise in Prevalence and Incidence of Chronic Diseases

The majority of people around the world suffer from chronic ailments. One in three adults worldwide has a chronic illness. Chronic diseases have impacted the health and quality of life of many people. Chronic illnesses, such as cancer, musculoskeletal and neurological conditions, chronic injuries, cardiovascular and gastrointestinal conditions, and cancer, can result in hospitalization, long-term incapacity, declining quality of life, and even death.

The mesenchymal stem cells penetrate and integrate into several organs, treat lung, spinal cord, autoimmune disorders, liver, bone, and cartilage diseases, and multiple organ damage. Using stem cells in treating the inflammatory, immune system, and degenerative tissue illnesses is an effective strategy. These are certain factors that propel the growth of the market.

• The Growing Need for Potent Treatments

One of the key drivers of market expansion is significant R&D investments. In addition, the growing need for potent treatments to reduce disease burden during the forecast period is another factor fueling the growth. For instance, the 5-year exploratory study on Parkinson's illness by Celavie Biosciences is ongoing as of May 2020. For the treatment of Parkinson's disease and other illnesses of the central nervous system, the business is developing regenerative stem cell therapies. Ok99 stem cell-based exploratory clinical studies for Parkinson's disease were effective, according to Celavie Biosciences. These are certain factors that propel the growth of the market.

Opportunities

• An Increase in R&D Activities

The increase in R&D activities and rising investments from public and private organizations will open up new possibilities for the market's growth rate. For instance, U.S. healthcare spending increased by 3.4% in 2021, per the Health Care Price Index (HCPI). The rise in growth indicates that federal spending fell sharply the year before, from USD 287,000 million in 2020 to USD 170,000 million in 2021.

The prompt treatment of chronic illnesses has increased the demand for stem cell therapy in the U.S. and Europe. Due to these positive elements, there is a greater need for drugs, and both major and minor market players are employing various techniques to meet this demand. This factor is expected to boost market growth.

• The Strategic Initiatives by Market Players

The leading companies are also working to develop targeted strategies, including product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth operation of the business, minimize risks, and boost the market's long-term growth in sales. This factor is expected to boost the market growth.

Restraints/Challenges

• High Cost Associated with the Treatment

Global cell therapy treatment market expansion has been hampered by its high cost. As people search for the newest therapy choices, cell treatments have emerged as a popular treatment option. Despite the enormous rise in demand for cell therapy, treatments are still exceedingly expensive. Depending on the situation, simple joint injections might cost up to $1,000, and more complex operations can cost up to $100,000. In the U.S., the average price of stem cell therapy will be between $4,000 and $8,000 per patient in 2020. Therefore, the growth of the cell therapy market is restrained by the high cost of the treatment.

• Supply Chain and Logistics

Cell therapies require specialized infrastructure and expertise for handling, storage, and transportation. Maintaining the integrity and viability of cells throughout the supply chain can be challenging, especially for therapies with short shelf lives or those that require cryopreservation.

This global cell therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global cell therapy market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In December 2021, Century Therapeutics, a biotechnology company, collaborated with Bristol Myers Squibb, a pharmaceutical company, and signed a license agreement to develop and commercialize up to four induced pluripotent stem cell ("iPSC") derived, engineered natural killer cell ("iNK") and T cell ("iT") programs for hematologic malignancies and solid tumors

Global Cell Therapy Market Scope

The global cell therapy market is segmented on the basis of technology, type, cell type, cell source, application, and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technology

• Somatic Cell Technology
• Cell Immortalization Technology
• Viral Vector Technology
• Genome Editing Technology
• Cell Plasticity Technology
• Three-Dimensional Technology

 Type

• Autologous
• Allogeneic

Cell Type

• Stem Cell
• Non-Stem Cell

Cell Source

• iPSCs
• Bone Marrow
• Umbilical Cord Blood-Derived Cells
• Adipose Tissues
• Neural Stem Cell

Application

• Musculoskeletal
• Cardiovascular
• Gastrointestinal
• Neurological
• Oncology
• Dermatology
• Wounds and Injuries
• Ocular
• Others

End User

• Hospitals and Clinics
• Regenerative Medicine Centres
• Diagnostic and Research Centres
• Others

Global Cell Therapy Market Regional Analysis/Insights

The global cell therapy market is analysed and market size insights and trends are provided by country, technology, type, cell type, cell source, application, and end-user as referenced above.

全球细胞治疗市场报告涵盖的国家包括美国、加拿大、墨西哥、德国、意大利、英国、法国、西班牙、荷兰、比利时、瑞士、土耳其、俄罗斯、欧洲其他地区、日本、中国、印度、韩国、澳大利亚、新加坡、马来西亚、泰国、印度尼西亚、菲律宾、亚太其他地区、巴西、阿根廷、南美洲其他地区、南非、沙特阿拉伯、阿联酋、埃及、以色列、中东和非洲其他地区。

北美在全球细胞治疗市场占据主导地位，因为它拥有强大的医疗设施基础、主要参与者的强大影响力、卓越的医疗保健基础设施以及大量患有慢性疾病的人群。

预计在 2023 年至 2030 年的预测期内，亚太地区将见证全球细胞治疗市场的显著增长，这得益于政府促进医疗保健的举措增多、人们健康意识的不断提高以及对治疗慢性病的先进医疗技术的需求不断增长、人口数量庞大以及对优质医疗服务的需求不断增长。

报告的国家部分还提供了影响单个市场影响因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税的影响和贸易路线。   

医疗保健基础设施增长安装基础和新技术渗透

全球细胞治疗市场还为您提供每个国家/地区资本设备医疗支出增长、全球细胞治疗市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对全球细胞治疗市场的影响的详细市场分析。数据涵盖 2015-2020 年的历史时期。

竞争格局和全球细胞治疗市场份额分析

全球细胞治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球细胞治疗市场的关注有关。

全球细胞治疗市场的一些主要参与者包括：

• Vericel Corporation（美国）
• Kolon TissueGene Inc.（美国）
• JCR制药有限公司（日本）
• MEDIPOST（韩国）
• 奥西里斯（美国）
• Stemedica Cell Technologies Inc.（美国）
• NuVasive Inc.（美国）
• Fibrocell Science Inc.（美国）
• Cellectis（法国）
• BioNTech IMFS（德国）
• Pluristem（以色列）
• Praxis Pharmaceuticals（美国）
• Genzyme 公司 (美国)
• 高级组织 (美国)
• 细胞换细胞（智利）
• PHARMICELL 有限公司 (韩国)
• ANTEROGEN.CO.LTD.（韩国）
• 诺华公司（瑞士）
• 葛兰素史克公司 (英国)
• CELGENE 公司（美国）
• 骨治疗公司（比利时）
• 细胞疗法（英国）
• Celyad（比利时）
• Regen BioPharma (美国)
• Cellular Therapeutics 有限公司 (中国)
• TxCell (法国)
• Advancells（印度）

SKU-28214